Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses

[1]  T. Ashizawa,et al.  Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse , 2016, Clinical Cancer Research.

[2]  Y. Kawakami,et al.  Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. , 2016, The Journal of investigative dermatology.

[3]  H. Suemizu,et al.  Predominant Development of Mature and Functional Human NK Cells in a Novel Human IL-2–Producing Transgenic NOG Mouse , 2015, The Journal of Immunology.

[4]  Y. Kawakami,et al.  Melanoma Cells Control Anti-Melanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. , 2015, The Journal of investigative dermatology.

[5]  B. Shi,et al.  Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma , 2014, Clinical Cancer Research.

[6]  M. Boniotto,et al.  Human Hematopoietic Reconstitution and HLA-Restricted Responses in Nonpermissive Alymphoid Mice , 2014, The Journal of Immunology.

[7]  S. Shimada,et al.  CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. , 2014, The Journal of investigative dermatology.

[8]  C. Rice,et al.  Characterization of Human Antiviral Adaptive Immune Responses during Hepatotropic Virus Infection in HLA-Transgenic Human Immune System Mice , 2013, The Journal of Immunology.

[9]  D. Greiner,et al.  Humanized mice for immune system investigation: progress, promise and challenges , 2012, Nature Reviews Immunology.

[10]  T. Sakurai,et al.  Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells , 2012, The Journal of Immunology.

[11]  Mamoru Ito,et al.  Current advances in humanized mouse models , 2012, Cellular and Molecular Immunology.

[12]  Mamoru Ito,et al.  T‐cell receptor gene therapy targeting melanoma‐associated antigen‐A4 inhibits human tumor growth in non‐obese diabetic/SCID/γcnull mice , 2012, Cancer science.

[13]  D. Schendel,et al.  NOD/scid IL-2Rgnull mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo , 2012, Journal of Translational Medicine.

[14]  T. Richie,et al.  Expression of HLA Class II Molecules in Humanized NOD.Rag1KO.IL2RgcKO Mice Is Critical for Development and Function of Human T and B Cells , 2011, PloS one.

[15]  S. Rosenberg,et al.  Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells , 2010, Journal of immunotherapy.

[16]  Satoshi Tanaka,et al.  Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγnull humanized mice , 2010, Proceedings of the National Academy of Sciences.

[17]  D. Greiner,et al.  Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease. , 2010, Methods in molecular biology.

[18]  A. Rothman,et al.  Dengue Virus Infection and Virus-Specific HLA-A2 Restricted Immune Responses in Humanized NOD-scid IL2rγnull Mice , 2009, PloS one.

[19]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[20]  D. Greiner,et al.  Human peripheral blood leucocyte non‐obese diabetic‐severe combined immunodeficiency interleukin‐2 receptor gamma chain gene mouse model of xenogeneic graft‐versus‐host‐like disease and the role of host major histocompatibility complex , 2009, Clinical and experimental immunology.

[21]  Mamoru Ito,et al.  Highly Sensitive Model for Xenogenic GVHD Using Severe Immunodeficient NOG Mice , 2009, Transplantation.

[22]  C. Rice,et al.  Priming of protective T cell responses against virus-induced tumors in mice with human immune system components , 2009, The Journal of experimental medicine.

[23]  J. Banchereau,et al.  Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. , 2008, Blood.

[24]  J. Peiris,et al.  Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models , 2007, Vaccine.

[25]  Asphalt Pavement Mixes,et al.  DEVELOPMENT OF A , 2011 .

[26]  K. Akashi,et al.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice , 2005 .

[27]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[28]  Markus G. Manz,et al.  Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.

[29]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[30]  Mamoru Ito,et al.  Functional CD5+ B cells develop predominantly in the spleen of NOD/SCID/gammac(null) (NOG) mice transplanted either with human umbilical cord blood, bone marrow, or mobilized peripheral blood CD34+ cells. , 2003, Experimental hematology.

[31]  Mamoru Ito,et al.  Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. , 2003, Blood.

[32]  Mamoru Ito,et al.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.

[33]  Y. Ueyama,et al.  Functional Human T Lymphocyte Development from Cord Blood CD34+ Cells in Nonobese Diabetic/Shi-scid, IL-2 Receptor γ Null Mice1 , 2002, The Journal of Immunology.

[34]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.